Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular inflammation and proteinuria.

FDA grants accelerated approval for Novartis's Vanrafia (atrasentan) for IgA nephropathy. The drug joins Tarpeyo and Filspari ...

Healthcare Analysts, along with Dr. David Eichenbaum, discuss the current state and future direction in Geographic Atrophy (GA) (relevant ...